Arvinas

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. 

CEO
John G. Houston
CEOJohn G. Houston
Employees
280
Employees280
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2013
Founded2013
Employees
280
Employees280

ARVN Key Statistics

Market cap
2.37B
Market cap2.37B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
362.79K
Average volume362.79K
High today
$46.68
High today$46.68
Low today
$44.25
Low today$44.25
Open price
$44.77
Open price$44.77
Volume
438.60K
Volume438.60K
52 Week high
$97.33
52 Week high$97.33
52 Week low
$34.90
52 Week low$34.90

Analyst ratings

86%

of 21 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

ARVN Earnings

-$1.32
-$0.11
$1.09
$2.30
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 2, Pre-Market
ActualExpected Nov 2, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.